Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2003 September;47(3) > The Quarterly Journal of Nuclear Medicine 2003 September;47(3):209-20

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

ORIGINAL ARTICLES  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 2003 September;47(3):209-20

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Radiopharmaceuticals for targeting the angiogenesis marker αvβ3

McQuade P. 1, KnIght L. C. 2

1 Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, MO, USA 2 Temple University School of Medicine Department of Diagnostic Imaging Philadelphia, PA, USA


PDF


A com­mon fea­ture of sol­id ­tumors is the for­ma­tion of new ­blood ves­sels (angio­gen­e­sis) with­in the ­tumor. A recep­tor ­called αvβ3 is ­found on endo­the­lial ­cells lin­ing new­ly grow­ing ­blood ves­sels at a high­er den­sity ­than on ­mature ­blood ves­sels. This recep­tor may pro­vide a tar­get for radio­lig­ands to per­mit imag­ing of a ­wide varie­ty of sol­id ­tumors. The radio­lig­ands may ­range ­from mac­ro­mol­e­cules ­such as ­native ­ligands or mono­clo­nal anti­bod­ies, to ­small pro­teins to ­very ­small pep­tides. The dif­fer­ing char­ac­ter­is­tics of ­these bio-mole­cules ­have an ­affect on tar­get deliv­ery and clear­ance ­time.

inizio pagina